[go: up one dir, main page]

DK0746317T3 - Sublingual eller bukkal farmaceutisk sammensætning - Google Patents

Sublingual eller bukkal farmaceutisk sammensætning

Info

Publication number
DK0746317T3
DK0746317T3 DK95912188T DK95912188T DK0746317T3 DK 0746317 T3 DK0746317 T3 DK 0746317T3 DK 95912188 T DK95912188 T DK 95912188T DK 95912188 T DK95912188 T DK 95912188T DK 0746317 T3 DK0746317 T3 DK 0746317T3
Authority
DK
Denmark
Prior art keywords
sublingual
pct
pharmaceutical composition
buccal
buccal pharmaceutical
Prior art date
Application number
DK95912188T
Other languages
Danish (da)
English (en)
Inventor
Leonardus Petrus C Delbressine
Johannes Hubertus Wieringa
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0746317(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0746317T3 publication Critical patent/DK0746317T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95912188T 1994-03-02 1995-03-01 Sublingual eller bukkal farmaceutisk sammensætning DK0746317T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94200521 1994-03-02
PCT/EP1995/000765 WO1995023600A1 (fr) 1994-03-02 1995-03-01 Composition pharmaceutique sublinguale ou buccale

Publications (1)

Publication Number Publication Date
DK0746317T3 true DK0746317T3 (da) 1999-03-22

Family

ID=8216678

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95912188T DK0746317T3 (da) 1994-03-02 1995-03-01 Sublingual eller bukkal farmaceutisk sammensætning

Country Status (23)

Country Link
US (1) US5763476A (fr)
EP (1) EP0746317B1 (fr)
JP (2) JP4099224B2 (fr)
KR (1) KR100330942B1 (fr)
CN (1) CN1079670C (fr)
AT (1) ATE167057T1 (fr)
AU (1) AU692530B2 (fr)
BR (2) BR9506924A (fr)
CA (1) CA2182981C (fr)
CZ (1) CZ284633B6 (fr)
DE (2) DE122010000050I2 (fr)
DK (1) DK0746317T3 (fr)
ES (1) ES2118584T3 (fr)
FI (1) FI117923B (fr)
FR (1) FR10C0056I2 (fr)
HK (1) HK1008417A1 (fr)
HU (1) HU225051B1 (fr)
LU (1) LU91751I2 (fr)
NO (2) NO308772B1 (fr)
NZ (1) NZ282394A (fr)
PL (1) PL180465B1 (fr)
RU (1) RU2139051C1 (fr)
WO (1) WO1995023600A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
AU2003211051A1 (en) * 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
CA2525366A1 (fr) * 2003-05-16 2004-11-25 Pfizer Products Inc. Combinaisons therapeutiques d'antipsychotiques atypiques avec des modulateurs de l'acide 4-aminobutanoique et/ou des medicaments anticonvulsivants
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
CA2539494C (fr) * 2003-09-22 2011-12-06 Baxter International Inc. Sterilisation a pression elevee afin de steriliser definitivement des preparations pharmaceutiques et des produits medicaux
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
WO2006040314A1 (fr) * 2004-10-15 2006-04-20 Pfizer Inc. Traitement de troubles bipolaires et symptomes associes
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
AR056306A1 (es) * 2005-04-07 2007-10-03 Organon Nv FORMA CRISTALINA ORTORRoMBICA DEL MALEATO DE ASENAPINA , COMPOSICIONES FARMACÉUTICAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MENTALES
ES2333980T3 (es) 2005-04-07 2010-03-03 N.V. Organon Compuestos intermediarios utiles en la preparacion de trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenzo(2,3:6,7)oxepino(4,5-c)pirrol.
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009156889A1 (fr) * 2008-06-25 2009-12-30 Pfizer Inc. Composés diaryle et leurs utilisations
WO2010127674A1 (fr) * 2009-05-06 2010-11-11 Sunin K/S Compositions transdermiques à base d'asénapine pour le traitement de troubles psychiatriques
AR077225A1 (es) 2009-06-24 2011-08-10 Organon Nv Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
TW201118102A (en) 2009-07-29 2011-06-01 Organon Nv Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
WO2011159903A2 (fr) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Maléate d'asénapine
EP2598496B1 (fr) 2010-07-29 2014-03-19 Laboratorios Lesvi, S.L. Nouveau procédé de synthèse de l'asénapine
WO2012038975A2 (fr) * 2010-09-22 2012-03-29 Msn Laboratories Limited Procédé de préparation de maléate de (3ars,12brs)-5-chloro-2-méthyl- 2,3,3a,12b-tétrahydro-1h-dibenzo[2,3:6,7]oxépino[4,5-c]pyrrole et composition pharmaceutique le contenant
BR112013012062B1 (pt) 2010-11-15 2020-06-02 Agenebio, Inc Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto
WO2012066565A2 (fr) 2010-11-16 2012-05-24 Cadila Healthcare Limited Maléate d'asénapine amorphe et forme cristalline et procédé pour leur préparation
EP2468750A1 (fr) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Formes polymorphiques de maléate d'asénapine et procédés de préparation
WO2012123325A1 (fr) 2011-03-11 2012-09-20 Medichem S.A. Nouvelles formes cristallines du sel de trans-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-1h-dibenzo[2,3:6,7] oxépino[4,5-c]pyrrole avec l'acide maléique
EP2524919A1 (fr) 2011-05-17 2012-11-21 Sandoz AG Nouveaux sels cristallins d'asénapine avec des di-acides et des tri-acides cristallins
EP2709615A1 (fr) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Forme cristalline monoclinique de maléate d'asénapine présentant une granulométrie spécifique
JP6014656B2 (ja) 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
WO2013041604A1 (fr) 2011-09-21 2013-03-28 Sandoz Ag Forme cristalline de maléate d'asénapine
EP2572703A1 (fr) 2011-09-21 2013-03-27 Hexal AG Forme pharmaceutique orale compressée pour maléate d'asénapine
CN102657635B (zh) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014090386A1 (fr) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Comprimé à désintégration orale contenant de l'asénapine
RU2015128794A (ru) 2012-12-20 2017-01-25 КАШИВ ФАРМА, ЭлЭлСи Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
CN103893139B (zh) * 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
CN103120688A (zh) * 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
WO2014116770A1 (fr) 2013-01-23 2014-07-31 Arx, Llc Production de constructions de doses unitaires
WO2014127786A1 (fr) 2013-02-22 2014-08-28 Zentiva, K.S. Composition pharmaceutique à désintégration orale comprenant de l'asénapine
IN2013MU02206A (fr) * 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20170007537A1 (en) * 2014-02-18 2017-01-12 Hetero Research Foundation Pharmaceutical compositions of asenapine
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
TR201509009A1 (en) * 2014-12-11 2017-02-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi THIN FILM STRIP OF ASENAPINE
CA2987081C (fr) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Procede pour la preparation de microparticules chargees de medicament
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
JP6686168B2 (ja) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102506333B1 (ko) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피흡수 치료 시스템
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
EP3562484B1 (fr) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Dérivés de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline utiles dans les traitements de troubles du snc
WO2018126140A1 (fr) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Composés organiques
MX387784B (es) 2017-03-24 2025-03-18 Intra Celular Therapies Inc Composiciones novedosas y metodos.
EP3644973B1 (fr) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine et polymère hybride acrylique silicone
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
IL279530B1 (en) 2018-06-19 2025-09-01 Agenebio Inc Benzodiazepine history, preparations, and methods for treating cognitive disorder
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020047241A1 (fr) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
EP3843738A4 (fr) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Nouvelles méthodes
CA3108558A1 (fr) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Nouvelles methodes
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
FR2480283A1 (fr) * 1980-04-10 1981-10-16 Science Union & Cie Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
JPS5967218A (ja) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA2027243A1 (fr) * 1989-10-17 1991-04-18 Everett H. Ellinwood, Jr. Trifluorobenzodiazepines intrabuccales et leur utilisation
US5496559A (en) * 1991-04-08 1996-03-05 Sumitomo Pharmaceuticals Company, Limited Porous solid formulations containing proteinaceous physiologically active substances
CA2095499A1 (fr) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Medicament-retard
EP0569096A1 (fr) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Préparation de dépôt

Also Published As

Publication number Publication date
FR10C0056I2 (fr) 2011-11-25
ES2118584T3 (es) 1998-09-16
BR1100625A (pt) 1999-12-28
EP0746317A1 (fr) 1996-12-11
NO2010024I1 (no) 2011-01-03
KR100330942B1 (ko) 2002-11-16
MX9603713A (es) 1997-12-31
CA2182981A1 (fr) 1995-09-08
NO963639L (no) 1996-10-30
FI117923B (fi) 2007-04-30
JPH09509674A (ja) 1997-09-30
LU91751I2 (fr) 2011-01-04
WO1995023600A1 (fr) 1995-09-08
EP0746317B1 (fr) 1998-06-10
CA2182981C (fr) 2006-10-17
DE69502939T2 (de) 1998-10-22
NO2010024I2 (no) 2012-04-10
JP4099224B2 (ja) 2008-06-11
DE122010000050I1 (de) 2011-05-05
JP2006342178A (ja) 2006-12-21
HUT76319A (en) 1997-08-28
JP4616810B2 (ja) 2011-01-19
FI963398A0 (fi) 1996-08-30
HU225051B1 (en) 2006-05-29
DE69502939D1 (de) 1998-07-16
FR10C0056I1 (fr) 2011-01-28
FI963398L (fi) 1996-08-30
CZ254196A3 (en) 1997-10-15
HU9602383D0 (en) 1996-10-28
NO963639D0 (no) 1996-08-30
ATE167057T1 (de) 1998-06-15
HK1008417A1 (en) 1999-05-07
NZ282394A (en) 1997-12-19
NO308772B1 (no) 2000-10-30
PL180465B1 (pl) 2001-02-28
DE122010000050I2 (de) 2011-07-21
CN1079670C (zh) 2002-02-27
CZ284633B6 (cs) 1999-01-13
RU2139051C1 (ru) 1999-10-10
US5763476A (en) 1998-06-09
AU1947895A (en) 1995-09-18
BR9506924A (pt) 1997-09-30
PL316080A1 (en) 1996-12-23
AU692530B2 (en) 1998-06-11
CN1143320A (zh) 1997-02-19

Similar Documents

Publication Publication Date Title
DK0746317T3 (da) Sublingual eller bukkal farmaceutisk sammensætning
CA2293823A1 (fr) Derives de homo-erythromycine a -9-deoxo-9a-aza-9aa substitution en position 4
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
AUPR213700A0 (en) Antiviral agents
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
CA2314154A1 (fr) Derives d'azepine et leur utilisation comme produits pharmaceutiques
SI0863752T1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
GR3034142T3 (en) Composition for the treatment or prevention of herpes
IL115004A (en) Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation